Employee turnover in the biopharma industry has reached unprecedented levels in recent years, causing a significant threat to intellectual property (IP) security. As the sector grapples with layoffs and recruitment shifts, there is an increasing need to understand how these workforce changes impact
Regeneron Pharmaceuticals recently hit a roadblock in its quest to bring its experimental multiple myeloma drug, linvoseltamab, to market. Although the drug promises significant benefits to patients, manufacturing flaws at a third-party facility have delayed FDA approval. This analysis delves into
The second quarter of 2024 marked a significant period for the top 20 biopharmaceutical companies as they navigated improving global markets. Bolstered by investor optimism and anticipated interest rate cuts from the US Federal Reserve, these companies showed robust performances and strategic
VGXI Inc., a prominent Contract Development and Manufacturing Organization (CDMO) specializing in nucleic acid biopharmaceuticals, is making significant strides in the biopharmaceutical industry. Their recent inclusion in the Biopharmaceutical Manufacturing Preparedness (BioMAP) Consortium
Fujifilm Diosynth Biotechnologies has taken a significant step toward bolstering its microbial production capabilities with the inauguration of a new microbial fermentation manufacturing facility in Billingham, UK. As a leading contract development and manufacturing organization (CDMO), the company
Tanvex BioPharma USA, Inc., a frontrunner in biologics development, has made significant strides by securing FDA approval for NYPOZI (filgrastim-txid) and advancing its Biologics License Application (BLA) for TX-05. These milestones underscore the company’s unwavering commitment to delivering h
